Donald Trump has confirmed that he’s actively considering one of the most significant changes to U.S. marijuana policy in decades — a potential move to reclassify the drug at the federal level.
His remarks came shortly after a high-profile fundraiser, where seats reportedly cost as much as $1 million apiece, drawing a powerful mix of cannabis industry leaders, Wall Street investors, and pharmaceutical executives. The former president revealed that his administration is “seriously looking at” whether marijuana should continue to be classified as a Schedule I substance — the same legal category as heroin and LSD — or be downgraded to Schedule III, alongside drugs like codeine and testosterone.
If enacted, the shift would not immediately legalize marijuana nationwide, but its ripple effects would be enormous. Criminal penalties would ease, medical research would surge, and businesses across the booming cannabis industry would gain long-awaited tax relief from restrictive federal laws. The change could also open the door for major pharmaceutical firms — long cautious about entering the market — to stake a claim in the multibillion-dollar green economy.
Trump, however, remains cautious. He called the issue “very complicated,” balancing between acknowledging the proven medical benefits of cannabis and voicing concern over potential social costs. Insiders say he’s aware that this decision could reshape not only federal drug policy but also voter sentiment ahead of the next election, especially among younger and independent voters who overwhelmingly support reform.
The move comes as President Joe Biden’s own effort to reclassify marijuana has stalled, leaving a political opening that Trump seems poised to exploit. In many ways, he’s walking a fine line — inheriting both the risks and rewards of a deeply divisive issue.
For now, the country waits. Whether Trump follows through or pulls back, his decision will reverberate through courtrooms, boardrooms, and living rooms alike — influencing criminal justice reform, medical innovation, and the future of a rapidly evolving American industry.
One thing is clear: if Trump acts, it won’t just be a policy change — it will mark a historic turning point in America’s relationship with marijuana.
